PROTACs
-
PROTACs Related Products (436)
Related Products (436)
-
DBt-10
0 ImagesCat. No.: HY-156746DBt-10 is a PROTAC degrader that targets and degrades BTK by recruiting DCAF1. It degrades BTK in TMD8 BTK-GFP/mCherry cells with a DC50 of 137 nM. DBt-10 induces CRL4DCAF1-dependent ubiquitination and proteasomal degradation of BTK, and retains BTK-degrading and antiproliferative activities in TMD8 cells that are resistant to CRBN-BTK PROTACs due to loss of CRBN expression. DBt-10 has a high survival window and exhibits extremely weak apoptosis-inducing effects on lymphoma cells. DBt-10 can be used for research on diffuse large B-cell lymphoma.
-
dIRF4-2
0 ImagesdIRF4-2 is a selective IRF4 PROTAC degrader with a DC50 value of 2.2 μM. dIRF4-2 forms a ternary complex between IRF4 and CRBN, inducing ubiquitination and proteasomal degradation of IRF4. dIRF4-2 downregulates MYC. dIRF4-2 exhibits anticancer activity against myeloma. dIRF4-2 acts as a chemical probe for investigating IRF4 function, mimicking the IRF4 gene knockout phenotype. dIRF4-2 can be used in the research of multiple myeloma.
-
FAK PROTAC B5
0 ImagesCat. No.: HY-143458CAS No.: 2471525-44-5FAK PROTAC B5 is a FAK PROTAC degrader with an IC50 of 14.9 nM. FAK PROTAC B5 induces FAK degradation via the ubiquitin-proteasome pathway by simultaneously binding to FAK and the CRBN E3 ligase. FAK PROTAC B5 inhibits the proliferation, migration and invasion of cancer cells. FAK PROTAC B5 can be used for the research of non-small cell lung cancer.
-
ZS3-046
0 ImagesCat. No.: HY-176457CAS No.: 3087879-97-5ZS3-046 is a potent TAF1 PROTAC degrader with a DC50 < 10 nM. ZS3-046 recruits the CRBN E3 ubiquitin ligase, promotes polyubiquitination and proteasomal degradation of TAF1, thereby activating p53 and downregulating c-Myc, and ultimately induces apoptosis of tumor cells. ZS3-046 can be used in research related to acute myeloid leukemia.
-
PROTAC ITK degrader 1
0 ImagesCat. No.: HY-149917PROTAC ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; DC50=3.6 nM in vivo in mice), with good plasma exposure levels. PROTAC ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC50=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo.
-
PROTAC ERα Y537S degrader-1
0 ImagesCat. No.: HY-145071CAS No.: 2667598-05-0
-
LO-4-25
0 ImagesCat. No.: HY-176067LO-4-25 is a CUL4DCAF16 based covalent PROTAC-like degrader. LO-4-25 induces degradation of the androgen receptor (AR) and androgen receptor truncation variant AR-V7. LO-4-25 covalently targets cysteine residues on CUL4DCAF16 to mediate degradation of neo-substrates. LO-4-25 triggers proteasome-dependent degradation of target proteins via CUL4DCAF16-mediated ubiquitination. LO-4-25 can be used for the research of androgen-independent prostate cancer.
-
CEP1347-VHL-02
0 ImagesCat. No.: HY-168026CEP1347-VHL-02 is a selective MLK3 PROTAC degrader that mediates MLK3 degradation via the ubiquitin-proteasome system, with a DC50 of 50-300 nM. After degrading MLK3, CEP1347-VHL-02 inhibits downstream JNK signaling, induces G2/M phase arrest and apoptosis in cancer cells, and suppresses their clonogenic, migratory and 3D sphere-forming abilities. CEP1347-VHL-02 can be used for the research of triple-negative breast cancer.
-
PROTAC EV-A71 Degrader-1
0 ImagesCat. No.: HY-182971PROTAC EV-A71 Degrader-1 is a PROTAC degrader targeting EV-A71 3D polymerase, with broad-spectrum activity against a variety of enteroviruses. PROTAC EV-A71 Degrader-1 induces the degradation of EV-A71 3D polymerase through the ubiquitin-proteasome and autophagy-lysosome pathways, and blocks viral replication. PROTAC EV-A71 Degrader-1 protects infected mice from death, alleviates tissue damage, and exhibits safety profiles. PROTAC EV-A71 Degrader-1 can be used in the research of enterovirus infections.
-
PROTAC HMGCR Degrader-1
0 ImagesCat. No.: HY-171823CAS No.: 2715104-45-1PROTAC HMGCR Degrader-1 is an orally active HMGCR PROTAC degrader with IC50 of 1.32 μM. PROTAC HMGCR Degrader-1 is a lactone prodrug of PROTAC HMGCR Degrader-2 (HY-181134). PROTAC HMGCR Degrader-1 achieves high plasma exposure of the active ingredient leading to robust HMGCR degradation and demonstrating promising cholesterol-lowering efficacy in vivo. PROTAC HMGCR Degrader-1 can be used for hyperlipidemia research.
-
dTAG-13-NEG TFA
0 ImagesCat. No.: HY-161157AdTAG-13-NEG TFA is a negative control of dTAG-13 (HY-114421). dTAG-13, a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest.
-
PROTAC KAT6 Degrader-2
0 ImagesCat. No.: HY-187357PROTAC KAT6 Degrader-2 is a KAT6A PROTAC degrader. PROTAC KAT6 Degrader-2 induces ubiquitination and proteasomal degradation of KAT6A. PROTAC KAT6 Degrader-2 exhibits high maximum fold activity in ternary complex formation assays. PROTAC KAT6 Degrader-2 can be used in studies related to breast cancer.
-
XYD190
0 ImagesCat. No.: HY-161494CAS No.: 3040121-23-8XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC50 of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia.
-
PROTAC EZH2 Degrader-30
0 ImagesCat. No.: HY-181359CAS No.: 3093642-31-7PROTAC EZH2 Degrader-30 (compound 67) is ais a PROTAC protein degrader targeting EZH2 with an IC50 of 6.22 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-30 can be used for the research of diffuse large B-cell lymphoma.
-
PROTAC SMARCA2/4 degrader-18
0 ImagesCat. No.: HY-163871CAS No.: 2568276-91-3
